Table 5. Meta-analysis of miR-149 rs2292832 polymorphism with cancer risk.

Variables	na	T vs. C				TT vs. CC				CT vs. CC				TT+CT vs. CC				TT vs. CT+CC
		OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2
Total	12	1.022(0.966–1.082)	0.449	0.283	16.8	1.002(0.880–1.140)	0.980	0.529	0.0	0.950(0.862–1.048)	0.306	0.971	0.0	0.975(0.892–1.065)	0.571	0.979	0.0	1.082(0.990–1.183)	0.083	0.109	36.2
Cancer type
Breast Cancer	2	1.078(0.860–1.350)	0.515	0.121	58.4	1.043(0.794–1.369)	0.763	0.361	0.0	0.977(0.821–1.162)	0.789	0.907	0.0	0.991(0.839–1.169)	0.911	0.656	0.0	1.170(0.819–1.670)	0.388	0.123	58.0
Colorectal Cancer	3	1.063(0.935–1.207)	0.352	0.979	0.0	1.072(0.807–1.424)	0.631	0.619	0.0	0.856(0.660–1.109)	0.238	0.996	0.0	0.942(0.738–1.202)	0.629	0.995	0.0	1.161(0.972–1.386)	0.100	0.628	0.0
Lung Cancer	2	1.090(0.762–1.560)	0.638	0.073	68.8	1.259(0.547–2.902)	0.588	0.058	72.1	0.986(0.764–1.273)	0.915	0.562	0.0	0.995(0.782–1.266)	0.966	0.238	28.2	1.234(0.598–2.545)	0.569	0.071	69.4
SCCHN	3	0.957(0.853–1.074)	0.458	0.688	0.0	0.863(0.661–1.126)	0.277	0.619	0.0	0.976(0.826–1.154)	0.776	0.323	0.0	0.966(0.839–1.111)	0.626	0.651	0.0	0.930(0.753–1.149)	0.503	0.742	0.0
other	2	1.200(0.997–1.444)	0.054	0.259	21.6	1.181(0.790–1.767)	0.417	0.271	17.3	0.825(0.550–1.239)	0.354	0.409	0.0	0.992(0.677–1.452)	0.965	0.312	2.0	1.388(1.083–1.778)	0.010	0.427	0.0
Ethnicity
Caucasian	4	1.014(0.904–1.139)	0.810	0.220	33.9	1.261(0.749–2.123)	0.383	0.102	56.2	0.991(0.848–1.160)	0.914	0.688	0.0	1.000(0.876–1.143)	0.996	0.767	0.0	1.286(0.761–2.171)	0.348	0.082	59.9
Asian	8	1.025(0.960–1.095)	0.463	0.255	22.0	0.986(0.851–1.143)	0.852	0.745	0.0	0.925(0.817–1.048)	0.222	0.949	0.0	0.955(0.849–1.075)	0.447	0.945	0.0	1.085(0.986–1.193)	0.094	0.154	34.3
Design
HB	4	0.984(0.891–1.087)	0.756	0.599	0.0	0.901(0.718–1.130)	0.368	0.733	0.0	0.960(0.821–1.123)	0.613	0.532	0.0	0.963(0.843–1.100)	0.577	0.831	0.0	1.012(0.860–1.190)	0.890	0.451	0.0
PB	6	1.029(0.957–1.107)	0.437	0.156	37.6	1.007(0.854–1.187)	0.934	0.645	0.0	0.943(0.826–1.077)	0.387	0.923	0.0	0.970(0.855–1.101)	0.636	0.917	0.0	1.092(0.979–1.217)	0.116	0.079	49.4
Sample size
≥1000	3	0.967(0.898–1.042)	0.383	0.901	0.0	0.924(0.778–1.098)	0.370	0.892	0.0	0.984(0.877–1.104)	0.781	0.950	0.0	0.971(0.871–1.084)	0.604	0.920	0.0	0.940(0.823–1.073)	0.357	0.891	0.0
<1000	9	1.106(1.012–1.209)	0.027	0.461	0.0	1.111(0.914–1.350)	0.292	0.442	0.0	0.870(0.724–1.046)	0.138	0.957	0.0	0.981(0.845–1.139)	0.802	0.902	0.0	1.217(1.078–1.373)	0.001	0.380	0.0
HWE
Yes	10	1.029(0.970–1.091)	0.346	0.261	19.8	1.019(0.892–1.164)	0.781	0.534	0.0	0.957(0.867–1.057)	0.389	0.977	0.0	0.981(0.893–1.078)	0.693	0.973	0.0	1.095(0.997–1.202)	0.058	0.090	40.2

SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; P: p value; P-H: P value of Q for heterogeneity test; I²: 0–25%, no heterogeneity; 25–50%, modest heterogeneity; 50%, high heterogeneity;

^aNumber of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H)<0.05 or I²>50%; otherwise, fixed effect model was used.